Format

Send to

Choose Destination
Int J Cancer. 2018 Dec 15;143(12):3169-3180. doi: 10.1002/ijc.31734. Epub 2018 Oct 16.

CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.

Luo J1,2, Chimge NO1,2, Zhou B1,2,3, Flodby P1,2, Castaldi A1,2, Firth AL1,2,4, Liu Y1,2, Wang H1,2, Yang C3,5, Marconett CN3,5,6, Crandall ED1,2,7,8,9, Offringa IA3,5,6, Frenkel B3,6,10, Borok Z1,2,3,6.

Author information

1
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
2
Hastings Center for Pulmonary Research, University of Southern California, Los Angeles, CA.
3
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
4
Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, Los Angeles, CA.
5
Department of Surgery, University of Southern California, Los Angeles, CA.
6
Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA.
7
Department of Pathology, University of Southern California, Los Angeles, CA.
8
Will Rogers Institute Pulmonary Research Center, Los Angeles, CA.
9
Department of Chemical Engineering and Materials Science, Viterbi School of Engineering, University of Southern California, Los Angeles, CA.
10
Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA.

Abstract

Claudins are a family of transmembrane proteins integral to the structure and function of tight junctions (TJ). Disruption of TJ and alterations in claudin expression are important features of invasive and metastatic cancer cells. Expression of CLDN18.1, the lung-specific isoform of CLDN18, is markedly decreased in lung adenocarcinoma (LuAd). Furthermore, we recently observed that aged Cldn18 -/- mice have increased propensity to develop LuAd. We now demonstrate that CLDN18.1 expression correlates inversely with promoter methylation and with LuAd patient mortality. In addition, when restored in LuAd cells that have lost expression, CLDN18.1 markedly attenuates malignant properties including xenograft tumor growth in vivo as well as cell proliferation, migration, invasion and anchorage-independent colony formation in vitro. Based on high throughput analyses of Cldn18 -/- murine lung alveolar epithelial type II cells, as well as CLDN18.1-repleted human LuAd cells, we hypothesized and subsequently confirmed by Western analysis that CLDN18.1 inhibits insulin-like growth factor-1 receptor (IGF-1R) and AKT phosphorylation. Consistent with recent data in Cldn18 -/- knockout mice, expression of CLDN18.1 in human LuAd cells also decreased expression of transcriptional co-activator with PDZ-binding motif (TAZ) and Yes-associated protein (YAP) and their target genes, contributing to its tumor suppressor activity. Moreover, analysis of LuAd cells in which YAP and/or TAZ are silenced with siRNA suggests that inhibition of TAZ, and possibly YAP, is also involved in CLDN18.1-mediated AKT inactivation. Taken together, these data indicate a tumor suppressor role for CLDN18.1 in LuAd mediated by a regulatory network that encompasses YAP/TAZ, IGF-1R and AKT signaling.

KEYWORDS:

AKT; IGF-1 receptor; YAP/TAZ; lung alveolar epithelial type II cells; xenograft

PMID:
30325015
PMCID:
PMC6263834
DOI:
10.1002/ijc.31734
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center